Pharmaceuticals, Biotechnology & Life Sciences

Insightful review of Dennis Cho’s August 19 sale at Twist Bioscience – why it’s a planned divestment, not a red flag, and what it means for investors.

Regeneron insider Joseph Lara’s recent buy‑sell pattern signals confidence while adding liquidity, hinting at potential strategic moves for shareholders.

Tempus AI insider sell‑to‑cover: CEO Eric Lefkofsky liquidates 132,591 shares at $49.61, a routine tax‑cover move that keeps his long‑term stake intact as the company pushes AI‑driven oncology trials toward FDA breakthrough status.

Insider buys spike as Amylyx’s CEO and team back Phase‑3 success, signaling confidence before avexitide’s FDA filing and potential market entry.

Viridian Therapeutics insider buying signals confidence: Chief Legal Officer sells and buys shares to balance liquidity and long‑term stake, reflecting bullish outlook.

Tax‑driven insider sales at Nektar Therapeutics show routine liquidity management, not a warning – focus on its oncology pipeline for upside.

Skye Bioscience insider sales spike: 1.4 m shares off the market, a reverse split looming and a potential Redx Pharma deal—what does this mean for investors?

Adaptive Biotechnologies insider buy: senior director Hershberg snaps up 15k shares at $6.32 vs. $25.49 market price, signaling confidence in future upside amid bullish trends.

Rocket Pharma’s latest insider sale shows routine RSU vesting, not a warning sign—investors should watch cumulative activity for liquidity clues.

Arrowhead Pharmaceuticals insider sale: Olukotun Adeoye sells 2,000 shares amid 2‑week price surge. Is it a confidence signal or a warning? Find out.